Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Polymorphisms in inflammatory pathway genes, host factors and lung cancer risk in Chinese female never-smokers.

Carcinogenesis·2011
Same author

Thymoquinone induces telomere shortening, DNA damage and apoptosis in human glioblastoma cells.

PloS one·2010
Same author

Distribution of PON1 polymorphisms PON1Q192R and PON1L55M among Chinese, Malay and Indian males in Singapore and possible susceptibility to organophosphate exposure.

Neurotoxicology·2009
Same author

Incidence, mortality and survival patterns of prostate cancer among residents in Singapore from 1968 to 2002.

BMC cancer·2008
Same author

Interethnic variability of plasma paraoxonase (PON1) activity towards organophosphates and PON1 polymorphisms among Asian populations--a short review.

Industrial health·2008
Same author

Association of blood lead and homocysteine levels among lead exposed subjects in Vietnam and Singapore.

Occupational and environmental medicine·2007

Related Experiment Video

Updated: Jun 2, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

Radioembolization for hepatocellular carcinoma using TheraSphere®.

Safiyya Mohamed Ali1

  • 1Liver Diseases Research Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia. ifizone@hotmail.com

Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association
|May 7, 2011
PubMed
Summary

Yttrium-90 (Y90) radioembolization shows promise for liver cancer (HCC) treatment. While effective for many patients, including those with portal vein thrombosis, further randomized trials are needed to confirm survival benefits before full recommendation.

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

Related Experiment Videos

Last Updated: Jun 2, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

Area of Science:

  • Hepatology
  • Oncology
  • Radiation Therapy

Background:

  • Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer.
  • Radioembolization using yttrium-90 (Y90) microspheres represents an emerging radiation therapy for HCC.
  • This review examines Y90 therapy with TheraSphere® for HCC, covering indications, efficacy, side effects, and future prospects.

Purpose of the Study:

  • To review the indications for Y90 radioembolization in HCC patients.
  • To evaluate the efficacy and safety profile of Y90 therapy for HCC.
  • To discuss the future directions and research needs for Y90 treatment in HCC.

Main Methods:

  • Literature review of clinical and scientific evidence for Y90 therapy.
  • Analysis of data from comprehensive reviews on radioembolization.
  • Consideration of conclusions from the Radioembolization Brachytherapy Oncology Consortium.

Main Results:

  • Y90 radioembolization is considered safe and effective for HCC, including cases with portal vein thrombosis.
  • Existing literature supports the use of this locoregional therapy.
  • No randomized clinical trials specifically on TheraSphere® have been completed.

Conclusions:

  • Y90 radioembolization demonstrates promising initial results for HCC.
  • A survival benefit has not yet been demonstrated in clinical studies.
  • Further large, randomized clinical trials are required to establish survival benefits and guide full recommendation.